… , afatinib, has … Lung 8 study demonstrated that afatinib significantly prolonged progression-free
and overall survival compared with erlotinib in patients with squamous cell lung carcinoma…

… LUX-Lung 8 was a randomised, controlled, phase 3 study … afatinib and erlotinib as
second-line treatment of patients with advanced squamous cell carcinoma (SCC) of the lung. We …

… squamous cell carcinoma (R/M HNSCC). This review systemically outlined and meta-analyzed
the afatinib … the efficacy of afatinib (second-line treatment) in NSCLC against erlotinib. In …

… phase 3 LUX-Lung 8 study, the ERBB family blocker, afatinib, … to erlotinib in patients with
relapsed/refractory squamous cell … including dyspnoea and overall lung cancer symptoms, were …

… The combination of afatinib with pembrolizumab is currently being studied in a phase I trial
in patients with EGFR-mutant NSCLC whose disease progressed during erlotinib treatment (…

… afatinib than erlotinib treatment. These data suggest that specific molecular characteristics
can be biomarkers for afatinib treatment … additional benefits from treatment with this drug. …

… afatinib versus erlotinib in patients with SCC of the lung … treated with afatinib in LUX-Lung
8 were deemed to derive long-term benefit from treatment (defined as ≥ 12 months of treatment…

… with clinical outcomes of afatinib- or erlotinib-treated patients with lung squamous cell …
afatinib vs erlotinib treatment and VS-G vs VS-P classification; (B) forest plot of OS by treatment …

… afatinib vs erlotinib (7.8 vs 6.8 months; HR 0.84, 95% CI 0.73–0.97; p=0.02). Overall AE profiles
were similar for afatinib and erlotinib … 44]; AEs leading to treatment discontinuation: n=79 […

… erlotinib groups. Five histologic transformations (two small cell, three squamous cell) were
detected in afatinib … in gefitinib group, and no transformations were detected in erlotinib group. …